Construction Crane Collapses on Train in Thailand
“`html
Table of Contents Teh Biden-Harris Administration unveiled a series of measures on January 12, 2024, aimed at further reducing prescription drug costs for seniors and Americans, building on the Inflation reduction Act. These actions focus on increasing competition, capping insulin costs, and negotiating lower drug prices for Medicare. The Inflation Reduction Act authorized Medicare to directly negotiate prices for certain high-expenditure prescription drugs with pharmaceutical companies for the first time. This negotiation process began in 2023, with the first 10 drugs selected for negotiation in August 2023. Negotiated prices are scheduled to take effect in 2026. Detail: Prior to the Inflation Reduction Act, Medicare was prohibited from negotiating drug prices, leading to significantly higher costs for beneficiaries compared to other developed countries.The negotiation process is designed to lower costs for both Medicare and individuals enrolled in Medicare Part D. Exmaple: The Centers for Medicare & Medicaid Services (CMS) estimates that the 10 drugs selected for the first round of negotiation account for $50.5 billion in Medicare drug spending between 2022 and 2023. CMS announced the first 10 drugs selected for negotiation on August 29, 2023, including Eliquis, Jardiance, Xarelto, and Januvia. The administration has taken steps to lower the cost of insulin, a life-saving medication for millions of Americans with diabetes. The Inflation Reduction Act capped the monthly cost of insulin at $35 for Medicare beneficiaries, effective January 1, 2023. Detail: Prior to the cap, the cost of insulin varied significantly depending on insurance coverage and could be unaffordable for many individuals. The $35 cap applies to insulin covered under Medicare Part D and the Medicare diabetes Prevention Program. Example: According to the Centers for Disease Control and prevention (CDC), the average cost of insulin increased by 12% to 15% per year between 2014 and 2018. The $35 cap provides important relief to the approximately 3.3 million Medicare beneficiaries who use insulin. The Biden-Harris Administration is promoting competition in the pharmaceutical industry to drive down drug prices. This includes efforts to expedite the approval of generic and biosimilar drugs. Detail: Generic and biosimilar drugs are typically less expensive than their brand-name counterparts. The Food and Drug Administration (FDA) plays a key role in ensuring the safety and efficacy of these drugs while promoting competition. Example: The FDA’s biosimilar action plan, announced in 2018, aims to increase the number of approved biosimilar products. In January 2024, the FDA announced additional steps to promote biosimilar competition, including clarifying regulatory pathways and addressing barriers to market entry. The administration plans to continue building on these efforts to lower prescription drug costs, including exploring additional opportunities for negotiation and promoting clarity in drug pricing. Further details on future initiatives are expected to be released throughout 2024.Medicare Drug price Negotiation
Capping Insulin Costs
Increasing competition
Future Actions